Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Bioline RX Ltd. (NASDAQ: BLRX) shares dropped 13.01 percent to close at $2.54 a share Tuesday. The stock traded between $2.50 and $2.56 on volume of 4.58 million shares traded. The company announced the pricing of an underwritten public offering of 8.4 million American Depositary Shares at a price of $2.50 per ADS. Shares of Bioline RX are down approximately 10.0 percent year-to-date.
Get more information on Bioline RX and free access to the in-depth equity report at: www.FiveStarEquities.com/BLRX
Corcept Therapeutics Inc. (NASDAQ: CORT) shares spiked 15.73 percent to close at $3.90 a share Tuesday. The stock traded between $3.40 and $3.99 on volume of 1.60 million shares traded. The company projects revenue for Korlym, a treatment for Cushing’s syndrome, to be in the range of $24.0 million and $28.0 million in 2014. Shares of Corcept Therapeutics are up approximately 20.0 percent year-to-date.
Get more information on Corcept Therapeutics and free access to the in-depth equity report at: www.FiveStarEquities.com/CORT
GT Advanced Technologies Inc. (NASDAQ: GTAT) shares surged 11.04 percent to close at $16.70 a share Tuesday. The stock traded between $15.85 and $16.83 on volume 17.57 million shares traded. Goldman Sachs has recently initiated coverage on the company with a “buy” rating. The company also reiterated guidance Monday. Shares of GT Advanced Technologies are up approximately 90.0 percent year-to-date.
Get more information on GT Advanced Technologies and free access to the in-depth equity report at: www.FiveStarEquities.com/GTAT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) shares soared 14.52 percent to close at $7.10 a share Tuesday. The stock traded between $7.05 and $8.35 on volume 7.42 million shares traded. The company announced that the FDA has lifted the clinical hold on Oxycyte, allowing them to proceed with the clinical development program in the US. Shares of Oxygen Biotherapeutics are up approximately 55.0 percent year-to-date.
Get more information on Oxygen Biotherapeutics free access to the in-depth equity report at: www.FiveStarEquities.com/OXBT
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact: Five Star Equities [email protected]